Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Safety and Influencing Factors of Ultrasound-guided Percutaneous Intramyocardial Septal Radiofrequency Ablation (Liwen Procedure) in The Treatment of Hypertrophic Cardiomyopathy

NCT06003478 is registered in ClinicalTrials.gov with Xijing Hospital as lead sponsor.

NCT NCT06003478
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06003478 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Safety and Influencing Factors of Ultrasound-guided Percutaneous Intramyocardial Septal Radiofrequency Ablation (Liwen Procedure) in The Treatment of Hypertrophic Cardiomyopathy
Lead sponsor
Xijing Hospital
Phase
Observational
Overall status
Unknown status
Start date
July 21, 2023
Completion date
May 30, 2024
Enrollment
486 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hypertrophic obstructive cardiomyopathy